Sciclone Pharma (SCLN) Guides FY15 Revs Above Consensus; May Consider Further Buybacks
Tweet Send to a Friend
Sciclone Pharmaceuticals, Inc. (Nasdaq: SCLN) reconfirmed its anticipated year-end 2014 revenue and non-GAAP earnings per share (EPS) guidance, and provided ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE